Link Between Non-Alcoholic Fatty Liver Disease and Atrial Fibrillation: A Systematic Review and Meta-Analysis

Abdul M. Minhas 1, Muhammad Shariq Usman 2, Muhammad S. Khan 3, Kaneez Fatima 4, Muhammad A. Mangi 1, Michael A. Illovsky 6

1. GME Internal Medicine, Orange Park Medical Center 2. Medical Student, Dow Medical College Karachi, Pakistan 3. Internal Medicine, John H Strgter l. Hospital of Cook County 4. Civil Hospital, Dow University of Health Sciences (DUHS), Karachi, Pakistan 5. Internal Medicine, Orange Park Medical Center 6. First Coast Cardiovascular Institute, Orange Park, Fl, Usa

Corresponding author: Muhammad S. Khan, shahzebkhan@gmail.com

Abstract

Association between non-alcoholic fatty liver disease (NAFLD) and various cardiovascular diseases has been demonstrated previously. Recent clinical studies have shown that increased circulating levels of γ glutamyl transpeptidase and liver transaminase, markers which are elevated in NAFLD, increase the risk of new-onset atrial fibrillation. We conducted a systematic review and meta-analysis of the available evidence to establish the possible association of increased chances of atrial fibrillation in patients with NAFLD. We extensively searched the PubMed, EMBASE, Cochrane Library, ISI Web of Science and Scopus databases to identify all possible studies that investigated the possible association of NAFLD with atrial fibrillation. Random effect models were used to pool the data between NAFLD and non-NAFLD group. I² testing was done to assess the heterogeneity of the included studies. Our primary outcome was atrial fibrillation. A total of three studies including 1044 patients in the NAFLD arm and 1016 in the placebo arm were included. On pooled analysis, it was observed that patients with NAFLD had 2.5 times significantly higher chance (OR = 2.47, CI = 1.30-4.66, p = 0.005) of developing new-onset atrial fibrillation. Our meta-analysis identifies the paucity of high-quality evidence regarding the association between NAFLD and atrial fibrillation. More studies are needed to confirm the link between NAFLD and atrial fibrillation.

Introduction And Background

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in many western countries [1-2]. Approximately 30% of the adult population in these countries are afflicted with NAFLD, and the prevalence further increases to 70-90% in those with obesity or diabetes [3]. In the past, a link between NAFLD and cardiovascular diseases has been demonstrated. Furthermore, recent clinical studies have shown that increased circulating levels of gamma-glutamyl transpeptidase (GGT) and liver transaminase increase the risk of new-onset atrial fibrillation (AF) [4-5]. Both these enzymes are known to be elevated in NAFLD [6]. This suggests that NAFLD could be a predictor of AF.

An association between the two disorders could have important clinical implications for patients with NAFLD, including different treatment approaches, along with an emphasis on prophylaxis against AF. The above information raises an important question: “What are the chances that a patient diagnosed with non-alcoholic fatty liver disease will also develop AF?” Using this question as our hypothesis, we conducted a systematic review and meta-analysis of relevant studies.

Review

Methods

Data Sources and Search Strategy

A systemic literature search was conducted using PubMed, EMBASE, Cochrane Library, ISI Web of Science, and Scopus using the search string (non-alcoholic fatty liver disease OR NAFLD OR non-alcoholic steatohepatitis OR non-alcoholic steatosis) AND (atrial fibrillation OR auricular fibrillation OR atrial flutter). Each database was searched from its inception to November 2016. Furthermore, references and citations of each article were manually screened to identify further relevant articles. All the results were transferred to EndNote and duplicate articles were identified and removed.

Inclusion and Exclusion Criteria
Our selection criteria included observational studies investigating the association between NAFLD and AF. Studies which employed well-established criteria for the diagnosis of NAFLD and AF were considered only. Furthermore, only those studies were considered in which the participants did not have a history of myocardial infarction at baseline. Our exclusion criteria included interventional studies, review articles, case reports, case series, book chapters, editorials, and animal studies. Articles dealing with alcoholic fatty liver disease and those concerned with non-atrial arrhythmias were excluded as well.

Data Extraction and Assessment of Study Quality

All articles obtained from the searches were screened by two reviewers, who were blinded to the findings of each other. Documents were selected only if they strictly matched the eligibility criteria. The articles were first shortlisted on the basis of titles and abstracts. Then, full texts were read to assess relevance. Any discrepancies during this process were solved by discussion until a consensus was reached. If a consensus could not be reached, a third reviewer was consulted.

Data from the included studies were extracted onto excel sheets by two independent investigators. Patient characteristics (authors, type of studies, the number of patients, year of publication, age, gender, diagnostic modality of NAFLD, AF assessment, outcome, mean follow-up time, adjustment of covariates, and results) were recorded. The Newcastle-Ottawa scale was used to assess the quality of the studies selected for meta-analysis [7]: a maximum of nine points to each cohort study (four for quality of selection, two for comparability, and three for quality of outcome and adequacy of follow-up) and a maximum score of 10 points to the cross-sectional study (five for quality of selection, two for comparability, and three for quality of outcome). Researches with a score of greater than seven are considered to have a good methodological quality and low bias.

Statistical Analysis

The association between NAFLD and AF was studied using odds ratios (OR). The heterogeneity between studies was approximated by using the Higgins I2 test (I2 <50% was considered acceptable) [8]. The data from component studies were pooled using a random effects model. Furthermore, a forest plot was created to visually assess the OR values and their corresponding 95% confidence intervals across studies. Publication bias was assessed using a contour funnel plot and Begg’s rank correlation test [9].

Results

Identification of Eligible Studies

In total, 344 potentially relevant abstracts were identified. After duplicates were removed, 63 unique abstracts remained. After examining the full-text publications, 21 publications seemed to meet the inclusion criteria. Of these, 18 were excluded for the following reasons: no available data on the outcome, review articles, alcohol use, non-atrial arrhythmias, and the diagnosis of NAFLD with liver enzymes. Finally, the remaining three studies to existing data met our selection criteria and were included in the meta-analysis.

The detailed search strategy is outlined using PRISMA flow sheet in Figure 1.
Three studies (n = 1044 in NAFLD group and n = 1016 in non-NAFLD group) were selected for meta-analysis [10-12]. The characteristics of these studies are summarized in Table 1. Two of the studies were prospective cohorts [10-11] while the other was a cross-sectional study [12]. All the included studies were published in the previous four years and were single-center studies. The method of assessment of NAFLD and AF was consistent across all studies. All the studies were of high methodological quality. Table 2 and Table 3 show a detailed breakdown of the quality assessment of each study.
### Table 1: Characteristics of the three included studies

| Study                          | Population | Mean Age (NAFLD/Non-NAFLD) | Males % (NAFLD/Non-NAFLD) | NAFLD Assessment                                                                 | AF Assessment                                                                 | Outcome (AF/Total) | Mean Follow-up Time | Adjustment of Covariates | Result          |
|-------------------------------|------------|-----------------------------|---------------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------|---------------------|------------------------|-----------------|
| Karajamaki AJ, 2015 Finland   | Total: 958 | NAFLD: 249 Non-NAFLD: 709   | 52±6/51±6 58/45           | Hepatic ultrasonography by a radiologist with 10-year experience                 | Based on standard 12-lead resting ECG. (noted in medical records)             | NAFLD: 37/249     | 16.3 years          | Age, sex, diabetes mellitus, BMI, waist circumference, smoking, serum ALT, systolic BP, Left atrial diameter, ANP, CAD and hs-CRP | COR 1.96 (1.29-2.97) |
| Targher G, 2013 Italy         | Total: 400 | NAFLD: 281 Non-NAFLD: 119   | 63±9/64±9 59.4/57.1       | Hepatic ultrasonography performed in all patients by an experienced radiologist, who was blind to the participants' details | Based on a standard 12-lead resting ECG. (noted in routine examination, or in medical records) | NAFLD: 38/281     | 10 years           | Age, sex, hypertension, LVH status and PR interval | COR 4.49 (1.6-12.9) |
| Targher G, 2013 Italy         | Total: 702 | NAFLD: 514 Non-NAFLD: 188   | 65±13/68±14 55.6/49.5     | Hepatic ultrasonography was performed in all patients by experienced radiologists, who were blinded to subjects' characteristics | Based on a standard 12-lead ECG done during hospital stay; or from medical history, (noted during hospital stay, or in medical records) | NAFLD: 76/514     | -                   | Age, sex, diabetes duration, HbA1c, LVH status, IHD, VHD and HF | COR 3.04 (1.54-6.02) |

ALT: Alanine aminotransferase; ANP: Atrial natriuretic peptide; BMI: Body mass index; BP: Blood pressure; CAD: Coronary artery disease; COR: Crude odds ratio; ECG: Electrocardiogram; HF: Heart failure; hs-CRP: High sensitivity C-reactive protein; IHD: Ischemic heart disease; LVH: Left ventricular hypertrophy; NAFLD: Non-alcoholic fatty liver disease; VHD: Valvular heart disease.

### Table 2: Quality assessment of cohort studies

***(A), *(B), ***(A+B): refer to 'Newcastle Ottawa Quality Assessment Scale for Cohort Studies' [7]**
Meta-Analysis of Primary Outcomes

The pooled ORs showed that patients with NAFLD were around 2.5 times more likely to develop new-onset AF (OR = 2.47, 95% CI = 1.30-4.66, p = 0.005). A forest plot outlining the meta-analysis is shown in Figure 2. We found no evidence of publication bias (Figure 3).

**FIGURE 2: Forest plot summarizing the pooling of studies**

| Study | ID | OR (95% CI) |
|-------|----|-------------|
| Karajanski AJ (2016) |  | 1.85 (0.99, 2.42) |
| Targher G. (2013) |  | 4.50 (1.57, 12.90) |
| Targher G (2013) |  | 3.04 (1.54, 6.02) |
| Overall (I-squared = 60.9%, p = 0.078) |  | 2.47 (1.30, 4.66) |

NOTE: Weights are from random effects analysis
Discussion
To the best of our knowledge, this is the first systematic review and meta-analysis to study the correlation between NAFLD and AF. Our findings indicate that patients with NAFLD have a statistically significant increased risk of developing AF. The three studies included in our meta-analysis report ORs that, while somewhat variable in magnitude, indicate a positive correlation between NAFLD and AF. Furthermore, in all studies, the association persists and remains statistically significant across a range of subgroup analyses. Although observational studies cannot prove causation, these three studies meet many of the Hill’s criteria for causation [13]. First, the association between NAFLD and AF is statistically significant and most likely not by chance. Second, consistency is seen across the studies – the relationship has been noted in different groups of people and in different locations. Third, a clear temporal association is seen in two of the studies [10-11], where NAFLD precedes the onset of AF. Fourth, there is a biological plausibility explaining how NAFLD could lead to AF. All these factors indicate possible causation and set the stage for future research to prove whether NAFLD actually causes AF.

A few hypothetical mechanisms by which NAFLD might lead to AF have been proposed. First, there is evidence that NAFLD independently causes systemic inflammation. The accumulation of fat within hepatocytes increases oxidative stress, which in turn causes the release of pro-inflammatory cytokines [14]. This escalates NAFLD to non-alcoholic steatohepatitis (NASH), and may also lead to systemic inflammation [15-16]. Inflammation is known to induce atrial fibrillation [17-18]. To make matters worse, AF seems to generate and sustain a pro-inflammatory environment, leading to a vicious cycle. Second, NAFLD has been shown to be associated with autonomic dysfunction [19-20]. The irregular sympathovagal stimulation in this condition is associated with an increased risk of atrial fibrillation [21-22] and could be the causal link between NAFLD and AF. Third, NAFLD has been shown to be an independent risk factor for cardiac diastolic dysfunction [23-24], which in turn has been reported to aggravate atrial fibrillation [25-26].

However, the results of our meta-analysis are limited by many factors. The total number of participants in our analysis was only 2,060 which are much less than the amount seen in other meta-analyses [27-28]. Also, the evidence was based on a pooled analysis of observational studies which is limited by the study design and presence of confounders. Furthermore, in two of the studies, all the participants were diabetic – this sample is not a valid indicator of the general population. Another limitation is the fact that included studies did not observe how the risk of AF varied with increasing amounts of fatty accumulation in the liver.

Conclusions
Our meta-analysis identifies the paucity of high-quality evidence regarding the association between NAFLD and AF. More studies are needed to confirm the link between NAFLD and AF.

Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might
have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Anteer QM, McPherson S, Day CP: How big a problem is non-alcoholic fatty liver disease. BMJ. 2011, 345:d3897. 10.1136/bmj.d3897
2. Clark JM, Brancazi FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2005, 98:960–967. 10.1111/j.1572-0241.2005.07486.x
3. Tarzberger GT, Day CP, Bonora E: Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010, 363:1541–1550. 10.1056/NEJMoa0912003
4. Alonso A, Misialek JR, Amin MA, et al.: Circulating levels of liver enzymes and incidence of atrial fibrillation: the atherosclerosis risk in communities cohort. Heart. 2014, 100:1511–1516. 10.1136/heartjnl-2014-305756
5. Sinner MF, Wang N, Fox CS, et al.: Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol. 2015, 111:219–224. 10.1016/j.jamcard.2012.09.021
6. Ghouri N, Preiss D, Sattar N: Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology, 2010, 52:1156–61. 10.1002/hep.23789
7. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2014). Accessed: March 15, 2017: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
8. Higgins JP, Thompson SG, Deeks JJ, et al.: Measuring inconsistency in meta-analyses. BMJ. 2003, 327:557–560. 10.1136/bmj.327.7443.557
9. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics, 1994, 50:1088–101. 10.2307/2533446
10. Karajimaki AI, Patsi OP, Savolainen M, et al.: Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population. PLoS One. 2015, 10:e0142957. 10.1371/journal.pone.0142957
11. Tarzberger G, Valbusa F, Bonapace S, et al.: Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One. 2013, 8:e57183. 10.1371/journal.pone.0057183
12. Tarzberger G, Mantovani A, Pichiari I, et al.: Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond), 2013, 125:301–509. 10.1042/CS20130036
13. Hill AB: The environment and disease: association or causation. Proc R Soc Med. 1965, 58:295–300.
14. Nduemele CE, Nasir K, Conceicao RD, et al.: Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol. 2011, 31:1927–1932. 10.1161/ATVBAHA.111.228262
15. Verdelho Machado M, Cortez-Pinto H: Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol. 2014, 20:12956–12980. 10.3748/wg.v20.i36.12956
16. Furukawa S, Fujita T, Shimabukuro M, et al.: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004, 114:1752–1761. 10.1172/JCI121625
17. Harada M, Van Wagoner DR, Natelli S: Role of inflammation in atrial fibrillation pathophysiology and management. Cir J. 2015, 79:495–502. 10.1253/circj.CJ-15-0158
18. Aviles RJ, Martin DO, Apperson-Hansen C, et al.: Inflammation as a risk factor for atrial fibrillation. Circulation. 2005, 108:5006–5010. 10.1161/01.CIR.0000103131.70301.4F
19. Liu YC, Hung CS, Wu YW, et al.: Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. PLoS One. 2015, 8:e61803. 10.1371/journal.pone.0061803
20. Sun W, Zhang D, Sun J, et al.: Association between non-alcoholic fatty liver disease and autonomic dysfunction in a Chinese population. QJM. 2015, 108:617–624. 10.1093/qjmed/hcv006
21. Perkinańska I, Ukkola O, Kiviniemi A, et al.: Heart rate variability findings as a predictor of atrial fibrillation in middle-aged population. J Cardiovasc Electrophysiol. 2014, 25:719–724. 10.1111/jce.12402
22. Shen MJ, Zipes DP: Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res. 2014, 114:1004–1021. 10.1161/CIRCRESAHA.113.302549
23. Graner M, Nyman K, Siren R, et al.: Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease. Circ Cardiovasc Imaging. 2014, 7:e001979. 10.1002/ccd.26807
24. Fotobolu H, Yaker T, Duman D, et al.: Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardioi J. 2010, 17:457–463.
25. Tsang TS, Gersh BJ, Appleton CP, et al.: Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002, 40:1636–1644. 10.1016/S0735-1097(02)02375-2
26. Nagarakanti R, Ezekowitz M: Diastolic dysfunction and atrial fibrillation. J Interv Card Electrophysiol. 2008, 22:111–118. 10.1007/s10840-008-9203-8
27. Du X, Liu L, Song W, et al.: Association between gout and erectile dysfunction: a systematic review and meta-analysis. PLoS One. 2016, 11:e0168784. 10.1371/journal.pone.0168784
28. Luni FK, Riaz H, Khan AR, et al.: Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2016, 10.1002/cct.26807